Aspire Biopharma Holdings, Inc.
ASBP
$5.17
-$0.35-6.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 302.78% | 433.39% | 459.34% | 381.70% | 279.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 331.60% | 552.17% | 561.72% | 419.35% | 255.62% |
| Operating Income | -331.08% | -551.86% | -561.72% | -419.35% | -255.62% |
| Income Before Tax | -1,770.33% | -3,215.38% | -3,924.61% | -3,575.06% | -284.41% |
| Income Tax Expenses | -- | -100.00% | 100.00% | 100.00% | 100.00% |
| Earnings from Continuing Operations | -1,768.91% | -3,207.38% | -3,920.54% | -3,571.31% | -284.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,768.91% | -3,207.38% | -3,920.54% | -3,571.31% | -284.13% |
| EBIT | -331.08% | -551.86% | -561.72% | -419.35% | -255.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1,046.91% | -2,567.89% | -4,078.92% | -5,394.50% | -28,475,100.00% |
| Normalized Basic EPS | -245.77% | -640.18% | -877.22% | -937.52% | -35,566,300.00% |
| EPS Diluted | -1,046.91% | -2,567.89% | -4,078.92% | -5,394.50% | -28,475,100.00% |
| Normalized Diluted EPS | -245.77% | -640.18% | -877.22% | -937.52% | -35,566,300.00% |
| Average Basic Shares Outstanding | 116.52% | -99.97% | -99.97% | -99.98% | -99.98% |
| Average Diluted Shares Outstanding | 116.52% | -99.97% | -99.97% | -99.98% | -99.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |